Roger C. Bone, MD and the evolving paradigms of sepsis

Contributions to Microbiology

Volumn 17, Issue , 2011, Pages 1-11

  Balk, Robert ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); HISTORY; HUMAN; PATHOLOGY; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME; UNITED STATES;

CLINICAL TRIALS AS TOPIC; HISTORY, 20TH CENTURY; HUMANS; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME; UNITED STATES;

EID: 84926111429     PISSN: 14209519     EISSN: 1662291X     Source Type: Book Series    
DOI: 10.1159/000323970     Document Type: Article

References (59)

1. Balk RA: Severe sepsis and septic shock. Crit Care Clin 2000;16:179-192.
2. Bone RC: The pathogenesis of sepsis. Ann Intern Med 1991;115:457-469.
3. Balk RA, Bone RC: The septic syndrome: Definition and clinical implications. Crit Care Clin 1989;5:1-8.
4. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310.
5. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554.
6. Dombrovsky VY, Martin AA, Sunderram J, et al: Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003. Crit Care Med 2007;35: 1244-1250.
7. Russell JA: Management of sepsis. N Engl J Med 2006;355:699-713.
8. Wheeler AP: Recent developments in the diagnosis and management of severe sepsis. Chest 2007;132: 1967-1976.
9. Bone RC, Balk RA, Cerra FB, et al: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101: 1644-1655.
10. Vincent JL: Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med 1997;25:372-374.
11. Bone RC, Fisher CJ Jr, Clemmer TP, et al: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-658.
12. Bone RC, Fisher CJ Jr, Clemmer TP, et al: Sepsis syndrome: A valid clinical entity. Crit Care Med 1989;17:389-393.
13. Zeni F, Freeman B, Natanson C: Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997;25:1095-1100.
14. Bone RC: A critical evaluation of new agents for the treatment of sepsis. JAMA 1991;266:1686-1691.
15. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis syndrome. JAMA 1995;273:934-941.
16. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibodyfragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebocontrolled, dose-ranging study. Crit Care Med 1996; 24:733-742.
17. Rangel-Frausto MS, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS). JAMA 1995;273: 117-123.
18. Levy MM, Fink MP, Marshall JC, et al: International Sepsis Definitions Conference. 2001 SCCM/ESICM/ ACCP/ATS/ SIS International Sepsis Definition Conference. Crit Care Med 2003;31:1250-1256.
19. Bone RC: Gram negative sepsis: Background, clinical features, and intervention. Chest 1991;100: 802-808.
20. Bone RC: Modulators of coagulation: A critical appraisal of their role in sepsis. Ann Intern Med 1992;152:1381-1389.
21. Bone RC, Grodzin CJ, Balk RA: Sepsis: A new hypothesis for pathogenesis of the disease process. Chest 1997;112:235-243.
22. Fourrier F, Chopin C, Goudemand J, et al: Septic shock, multiple organ failure, and disseminated intravascular coagulation. Chest 1992;101:816-823.
23. Balk RA: Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock. Crit Care Clin 2000;16:337-352.
24. Bone RC: Gram-negative sepsis: A dilemma of modern medicine. Clin Microbiol Rev 1993;6:57-68.
25. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471-1477.
26. Petrak RA, Balk RA, Bone RC: Prostaglandins, cyclo-oxygenase inhibitors, and thromboxane synthetase inhibitors in the pathogenesis of multiple systems organ failure. Crit Care Clin 1989;5: 303-314.
27. Dinarello CA: Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 1997;112:S321-S329.
28. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119: 771-778.
29. Symeonides S, Balk RA: Nitric oxide in the pathogenesis of sepsis. Infect Dis Clin North Am 1999;13: 449-463.
30. Bone RC: A critical evaluation of new agents for the treatment of sepsis. JAMA 1991;266:1686-1691.
31. Hinshaw LB, Archer LT, Beller-Todd BK, et al: Survival of primates in lethal septic shock following delayed treatment with steroid. Circ Shock 1981;8: 291-300.
32. Schumer W: Steroids in the treatment of clinical septic shock. Ann Surg 1976;184:333-339.
33. Sprung CL, Caralis PV, Marcial EH, et al: The effects of high-dose corticosteroids in patients with septic shock: A prospective, controlled study. N Engl J Med 1984;311:1137-1143.
34. Veterans Administration Systemic Sepsis Cooperative Study Group: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987; 317:659-665.
35. Dellinger RP: Steroid therapy of septic shock: The decision is in the eye of the beholder. Crit Care Med 2008;36:1987-1989.
36. Finfer S: Corticosteroids in septic shock. N Engl J Med 2008;358:188-190.
37. Beale R, Janes JM, Brunkhorst FM, et al: Global utilization of low-dose corticosteroids in severe sepsis and septic shock: A report from the PROGRESS registry. Crit Care 2010;14:R102.
38. Goodman S, Sprung CL: The international sepsis forum's controversies in sepsis: Corticosteroids should be used to treat septic shock. Crit Care 2002; 6:381-383.
39. Oppert M, Schindler R, Husung C, et al: Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 2005;33:2457-2464.
40. Bollaert PE, Charpentier C, Levy B, et al: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645-650.
41. Briegel J, Forst H, Haller M, et al: Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, singlecenter study. Crit Care Med 1999;27:723-732.
42. Annane D, Sebille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisones on mortality in patients with septic shock. JAMA 2002;288:862-871.
43. Sprung CL, Annane D, Keh D, et al: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-124.
44. Natanson C, Hoffman WD, Suffredini AF, et al: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994;120:771-783.
45. Bone RC: Why sepsis trials fail. JAMA 1996;276: 565-566.
46. Bernard GR, Vincent JL, Laterre PF, et al: Recombinant human protein C worldwide evaluation in severe sepsis (PROWESS) study Group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344: 2051-2059.
47. Rivers E, Nguyen B, Havstad S, et al: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345: 1368-1377.
48. Finfer S, Bellomo R, Boyce N, et al: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350: 2247-2256.
49. Brunkhorst FM, Engel C, Bloos F, et al: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-139.
50. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
51. Hollenberg SM: Vasopressor support in septic shock. Chest 2007;132:1678-1687.
52. Patel GP, Grahe JS, Sperry M, et al: Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock 2010;33:375-380.
53. De Backer D, Biston P, Devriendt J, et al: Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362:779-789.
54. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34: 1589-1596.
55. Durairah L, Schmidt GA: Fluid therapy in resuscitated sepsis: Less is more. Chest 2008;133:252-263.
56. Russell JA, Walley KR, Singer J, et al: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-887.
57. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al: Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742-2751.
58. Bellomo R, Chapman M, Finfer S, et al: Low-dose dopamine in patient with early renal dysfunction: A placebo-controlled randomized trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000;356:2139-2143.
59. Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-1308.